Mr Glass said the trial had three primary endpoints including the Glasgow Coma Scale, the Portland Adaptability Index and biological outcomes including seizures as measured by electro-encephalogram, blood biomarkers of cell death and intra-cranial pressure.
He said the FDA had approved the trial meeting any one of the three efficacy endpoints.
I'm only highlighting, but won't comment, I promise.
drug development in traumatic brain injury, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.13 |
Change
-0.260(1.69%) |
Mkt cap ! $1.881B | |||
| Open | High | Low | Value | Volume |
| $15.45 | $15.45 | $15.03 | $5.239M | 344.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 2886 | $15.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 190 | 5 |
View Market Depth
| Last trade - 15.16pm 21/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |